Tapering Heart Failure Medications for Heart Function Recovery
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- Chungnam National University Hospital · Other
This trial is looking for patients who have improved heart function after treatment for heart failure. Participants will either continue their current medications or work with their healthcare team to reduce them.
You may be able to join if
- I have an initial ejection fraction less than 40%.
- My latest ejection fraction is over 50%.
- I have been taking more than 3 heart failure medications.
You may not be able to join if
- I am under 18 years old.
- I have high blood pressure that is not controlled.
- I have had heart surgery in the last 6 months.
- I have severe valve disease.
- I have an arrhythmia that needs treatment to control my heart rate.
- I have kidney disease with protein in my urine.
- I am pregnant.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityStudy start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Loading trial locations…